about
Clinical lung xenotransplantation--what donor genetic modifications may be necessary?Immunogenicity in xenogeneic scaffold generation: antigen removal vs. decellularizationBovine alpha1,3-galactosyltransferase catalytic domain structure and its relationship with ABO histo-blood group and glycosphingolipid glycosyltransferases.Immunobiology of liver xenotransplantation.The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies.Overcoming the barriers to xenotransplantation: prospects for the futureMixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejectionPharmacotherapeutic agents in xenotransplantation.Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.Carbohydrates in xenotransplantation.The expression and distribution of α-Gal gene in various species ocular surface tissue.Frankenswine, or bringing home the bacon: How close are we to clinical trials in xenotransplantation?Cytokine secretion depends on Galalpha(1,3)Gal expression in a pig-to-human whole blood modelIs there a correlation between anti-pig antibody levels in humans and geographic location during childhood?Xenotransplantation--the future of corneal transplantation?The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options.Biomaterials: so many choices, so little time. What are the differences?Lectin interactions with alpha-galactosylated xenoantigens.Modulation of the in vivo primate anti-Gal response through administration of anti-idiotypic antibodies.Adenovirus-mediated expression of pig alpha(1, 3) galactosyltransferase reconstructs Gal alpha(1, 3) gal epitope on the surface of human tumor cells.Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.The pathobiology of pig-to-primate xenotransplantation: a historical review.Modifying the sugar icing on the transplantation cake.Both IgG and IgM anti-pig antibodies induce complement activation and cytotoxicity.Pig xenogeneic antigen modification with green coffee bean alpha-galactosidase.Production of human monoclonal antibodies against Galalpha(1-3)Gal.Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum.Distribution of the alphaGal- and the non-alphaGal T-antigens in the pig kidney: potential targets for rejection in pig-to-man xenotransplantation.Normal human serum contains high levels of anti-Gal alpha 1-4GlcNAc antibodies.Different approaches to heart valve decellularization: A comprehensive overview of the past 30 years.Swine Leukocyte Antigen Class II Is a Xenoantigen.Expression analysis of an α-1, 3-galactosyltransferase, an enzyme that creates xenotransplantation-related α-Gal epitope, in pig preimplantation embryos.Cross-reactivity between decellularized porcine corneal lamellae for corneal xenobridging and subsequent corneal allotransplants.Method for perfusion decellularization of porcine whole liver and kidney for use as a scaffold for clinical-scale bioengineering engrafts.A new chemical approach to human ABO histo-blood group type 2 antigens.Xenotransplantation
P2860
Q26823663-A48FB77D-9654-4D94-8111-45EACB8AE360Q26851589-DA1E21FD-D02A-41E0-BF0B-6D441D4F000DQ27629621-B9B4A13F-A036-4728-B14F-42161113E46CQ33403888-01FDA003-4454-4B24-918E-B379E05E42C7Q33742186-4C978BCE-47F2-4576-96A4-C50BD14A3C1FQ33801035-82917F8C-6022-42AD-BF2B-5B99D2CDEAC7Q33853565-3EF60F00-0B11-4F28-880D-B86B1887A1A5Q34182104-13A075EA-A968-4D37-BEFD-49C5D882679CQ35940563-553854F7-6457-4D56-AA08-903B4D80CDFAQ36169039-A217AB4D-93BB-48F7-B058-39F2F9223A46Q36201681-842A6470-4D69-4F9C-8309-68F9A8DCE402Q36358620-71D1E20C-B37F-400A-BF27-8A855C8B7F1BQ37080101-F35893F2-F777-4077-B302-38063DC9E143Q37228094-961A2018-8334-4BB1-98DE-990784F9350BQ37401609-41FDEF8D-CD79-45EA-87FA-9CBF1CFDEB08Q37811749-DBC02547-8B26-4030-ABC4-5A3E39D72582Q38191251-F6459AA0-1A44-44FB-A502-1D369BD92924Q38272968-D522AAD5-0FD0-4DF4-86C9-EFE125E2235EQ38288245-62F3102E-E720-41C6-9B29-270615EAE5E9Q38291105-87827185-1F3D-4110-B291-6398C646B54FQ38299022-864C70A3-FC2F-40BD-B3FA-C2E8313F27DAQ38341233-B4C25EB4-7C48-4BE9-AAE6-847494AC8843Q38712532-30324D7D-5592-48CF-8267-7A0875F87FCDQ38758339-1B504B6C-76D0-4939-A8A8-7D689B996443Q40826290-0922E6D7-5E4D-44B9-8D5F-1E4DE42BC225Q40895910-B16E1700-1373-4EA9-904B-5D6BFC70579BQ43975629-D3D29FEE-C6CF-46F8-962D-D985CE0D4E82Q44173335-60DC694F-4DA2-46A2-9226-9E858C5A31F0Q46732680-568D6FD6-5377-4CA5-837E-4A2E9BB12FFBQ46908625-53462360-040E-48F0-ABB9-6C47759BF368Q47422814-682B3471-F8CC-4631-A050-5F6B910436A5Q47897051-BFC31F74-4057-4DB6-B1DA-FBF4A23B5AB1Q48657264-7F320E7E-C1FA-4CD1-8CA8-4409EA6DB9AAQ50868940-89B8BAED-37A9-4E91-BCA2-35BE0208D19DQ51045766-8DC433CD-2BDD-42D0-A7E1-EE12B50A86E2Q54377942-1D2C4CBF-2BD0-46F0-A272-DBA607502295Q56883877-367C658A-F1F0-4C04-8818-23D7379235EF
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Xenoantigens and xenoantibodies.
@en
type
label
Xenoantigens and xenoantibodies.
@en
prefLabel
Xenoantigens and xenoantibodies.
@en
P2860
P1433
P1476
Xenoantigens and xenoantibodies.
@en
P2093
P2860
P356
10.1111/J.1399-3089.1998.TB00003.X
P577
1998-02-01T00:00:00Z